Novo Nordisk A/S (NVO) EPS Basic: 4.27
Is Novo Nordisk A/S’s EPS basic high or low?
Novo Nordisk A/S's EPS basic of 4.27 is 79% above its 5-year average of 2.39, near the high end of its 5-year range (1.48–4.27).
26.41% above its 12-month average of 3.38.
NVO EPS Basic Chart
NVO Average EPS Basic Chart
NVO Current vs Average EPS Basic Chart
NVO EPS Basic Metrics
EPS BASIC
4.27
EPS BASIC AVG TTM
3.38
EPS BASIC AVG 3Y
2.82
EPS BASIC AVG 5Y
2.39
EPS BASIC AVG 10Y
1.83
EPS BASIC AVG 15Y
1.19
EPS BASIC AVG 20Y
0.94
CURRENT VS TTM AVG
+26.41%
CURRENT VS 3Y AVG
+51.44%
CURRENT VS 5Y AVG
+78.57%
CURRENT VS 10Y AVG
+133.80%
CURRENT VS 15Y AVG
+258.40%
CURRENT VS 20Y AVG
+353.28%
Novo Nordisk A/S EPS Basic Formula & Definition
EPS Basic is earnings per common share before the effect of potentially dilutive securities. It shows how much profit is attributable to each current common share.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EPS Basic FAQ
- What is the EPS basic for Novo Nordisk A/S (NVO)?
- The EPS basic for NVO stock is 4.27.
- Is Novo Nordisk A/S's EPS basic high or low?
- Novo Nordisk A/S's EPS basic of 4.27 is 79% above its 5-year average of 2.39, near the high end of its 5-year range (1.48–4.27).
- What is the TTM average EPS basic for Novo Nordisk A/S (NVO)?
- The TTM average EPS basic for NVO stock is 3.38.
- What is the 3Y average EPS basic for Novo Nordisk A/S (NVO)?
- The 3Y average EPS basic for NVO stock is 2.82.
- What is the 5Y average EPS basic for Novo Nordisk A/S (NVO)?
- The 5Y average EPS basic for NVO stock is 2.39.
- What is the 10Y average EPS basic for Novo Nordisk A/S (NVO)?
- The 10Y average EPS basic for NVO stock is 1.83.
- What is the 15Y average EPS basic for Novo Nordisk A/S (NVO)?
- The 15Y average EPS basic for NVO stock is 1.19.
- What is the 20Y average EPS basic for Novo Nordisk A/S (NVO)?
- The 20Y average EPS basic for NVO stock is 0.94.
Novo Nordisk A/S EPS Basic History
| DATE | EPS BASIC |
|---|---|
| 2025-12-31 | 3.62 |
| 2024-12-31 | 3.14 |
| 2023-12-31 | 2.76 |
| 2022-12-31 | 1.76 |
| 2021-12-31 | 1.59 |
| 2020-12-31 | 1.48 |
| 2019-12-31 | 1.23 |
| 2018-12-31 | 1.23 |
| 2017-12-31 | 1.24 |
| 2016-12-31 | 1.06 |
| 2015-12-31 | 0.99 |
| 2014-12-31 | 0.82 |
| 2013-12-31 | 0.87 |
| 2012-12-31 | 0.69 |
| 2011-12-31 | 0.53 |
| 2010-12-31 | 0.44 |
| 2009-12-31 | 0.35 |
| 2008-12-31 | 0.29 |
| 2007-12-31 | 0.26 |
| 2006-12-31 | 0.18 |
| 2005-12-31 | 0.14 |
| 2004-12-31 | 0.14 |
| 2003-12-31 | 0.12 |
| 2002-12-31 | 0.09 |
| 2001-12-31 | 0.09 |
| 2000-12-31 | 0.07 |
| 1999-12-31 | 0.05 |
| 1998-12-31 | 0.05 |
| 1997-12-31 | 0.05 |
| 1996-12-31 | 0.04 |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar